Courtesy of Dr. Carlos Fava One of the present challenges of TAVR is bicuspid aortic valve stenosis (AS), since it presents a different distribution and structure, associated to greater and more irregular calcification. There are only small series of devices and their use is still controversial. The study analyzed 561 patients with severe bicuspid<a href="https://solaci.org/en/2017/04/27/bicuspid-aortic-valve-stenosis-still-challenging-for-tavr/" title="Read more" >...</a>
Two recent articles featured in JACC Cardiovascular Interventions showed that short term (at 30 days) outcomes of patients treated with the next-generation self-expanding Medtronic Evolut R valves could present several advantages compared to the original CoreValve, including recapturability. Both analyses reported similar rates of all-cause mortality and stroke. The study carried out by Dr. Jeffrey Popma as<a href="https://solaci.org/en/2017/02/23/evolut-r-clinical-results-might-be-better-than-those-for-first-generation-corevalve/" title="Read more" >...</a>
This study sought to clarify the incidence and predictors of hypoattenuated leaflet thickening (assumed as leaflet thrombosis) imaging in transcatheter bioprosthesis. This study involved 70 consecutive patients who underwent transcatheter aortic valve replacement with the Edwards SAPIEN-XT device and were subjected to follow-up at 6 months and 1 year through multislice computed tomography (CT), echocardiographic data, and<a href="https://solaci.org/en/2017/01/21/transcatheter-valve-thrombosis-predictors-incidence-and-events/" title="Read more" >...</a>
The aim of this study was to evaluate the long-term performance of transcatheter aortic valve replacement (TAVR) and surgically-implanted valves through longitudinal echocardiographic follow-up of the PARTNER I trial patients. The study included all patients receiving TAVR or undergoing surgery who had a post-implant echocardiogram at five years analyzed for peak systolic velocity, mean gradient,<a href="https://solaci.org/en/2017/01/13/tavr-vs-surgery-valve-performance-at-five-years-partner-i/" title="Read more" >...</a>
Patients with low-flow, low-gradient severe symptomatic aortic stenosis associated with severe impairment of the left ventricular systolic function have shown acceptable outcomes after transcatheter aortic valve replacement (TAVR), according to the multicenter TOPAS-TAVI registry, which demonstrated a relatively low 30-day mortality rate. Considering the very high risk presented by this population involved, a 30-day<a href="https://solaci.org/en/2017/01/06/tavr-in-low-flow-low-gradient-aortic-stenosis-and-severe-impairment-of-systolic-function/" title="Read more" >...</a>
Courtesy of Dr. Agustín Vecchia. Surgery is the treatment of choice for patients with symptomatic aortic insufficiency and/or ventricular dilatation or decreased ventricular function. The broad implementation of transcatheter aortic valve replacement (TAVR) in patients with aortic stenosis, the emergence of new devices, and the experience acquired by operators have brought this treatment to off-label indications such<a href="https://solaci.org/en/2016/12/13/tavr-in-pure-aortic-insufficiency-yes-or-no/" title="Read more" >...</a>
Courtesy of Dr. Carlos Fava. The femoral approach has been the gold standard for the transcatheter aortic valve replacement procedure (TAVR); however, it is anatomically unsuitable for an important number of patients, and these require a different approach. At present, there is little evidence in support of the transapical or transaortic access sites as<a href="https://solaci.org/en/2016/12/02/transapical-and-transaortic-tavr-valid-alternatives-to-the-transfemoral/" title="Read more" >...</a>
There are limited data on the incidence, clinical implications, and predisposing factors of valve thrombosis in patients who underwent transcatheter aortic valve replacement (TAVR). This study aimed at determining such information through multislice computed tomography (CT). This trial included 460 consecutive patients who underwent TAVR with a balloon-expandable Edwards Sapien XT or Sapien 3 (Edwards Lifesciences,<a href="https://solaci.org/en/2016/11/13/valve-thrombosis-after-tavr-larger-diameter-valves-and-no-warfarin-as-predictors/" title="Read more" >...</a>
This study summarizes all available evidence on transcatheter aortic valve replacement (TAVR) for the treatment of native pure aortic regurgitation. Surgical replacement is the standard of care for pure aortic regurgitation. However, there are many reports of cases and small studies in which high-risk patients with pure aortic regurgitation were treated with TAVR. <a href="https://solaci.org/en/2016/11/01/tavr-in-pure-aortic-regurgitation-is-associated-with-lower-mortality-rates/" title="Read more" >...</a>
SENTINEL One of the new devices assessed at London Valves was Sentinel, which is made up of two independent filters. The larger filter is deployed in the brachiocephalic trunk, and the smaller filter is deployed in the left common carotid artery. The study included 22 patients and the device was deployed successfully in 20 of them<a href="https://solaci.org/en/2016/10/20/cerebral-protection-in-tavr-studies-presented-at-london-valves/" title="Read more" >...</a>